ESMO Congress 2021

Findings from international registries improve knowledge on how to manage cancer care in the pandemic era

Initial delays to antibody production are followed by similar levels of vaccine efficacy after a second vaccine dose

Findings from the third ESMO Resilience Task Force survey highlight the detrimental effect of long working hours and changes to clinical routine on future career plans

Practice-changing results were also presented in bronchopulmonary and non-pancreatic NETs with somatostatin analogues and VEGFR inhibitors

Latest findings on the use of single-agent and combination immunotherapy are not conclusive, despite being promising

Projections by the European Commission – Joint Research Centre from Ispra, Italy, estimate a 21.4% increase in cancer cases in 20 years’ time 

Malignant pleural mesothelioma is a rare and fatal disease with very little improvement in survival in recent years, mirroring very limited therapeutic advances. After a long-awaited time, improvement in patient survival was achieved with the introduction of nivolumab plus ipilimumab in the first-line setting, as demonstrated in the CheckMate 743 trial.

Findings from several studies highlight the increasing utility of this approach to identify druggable genetic alterations 

Most, but not all, patients on chemotherapy or immunotherapy for solid tumours had an adequate immune response after two doses of mRNA-1273 vaccination, with no new safety concerns 

In the NeoTRIPaPDL1 study, combining information from biomarker analysis at baseline and during treatment was informative on clinical benefit